Elite Pharmaceuticals Inc
OTC:ELTP
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Elite Pharmaceuticals Inc
Short-Term Investments
Elite Pharmaceuticals Inc
Short-Term Investments Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Short-Term Investments | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Elite Pharmaceuticals Inc
OTC:ELTP
|
Short-Term Investments
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Short-Term Investments
$10.8B
|
CAGR 3-Years
-13%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
-8%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Short-Term Investments
$464m
|
CAGR 3-Years
53%
|
CAGR 5-Years
-18%
|
CAGR 10-Years
-13%
|
|
|
|
Pfizer Inc
NYSE:PFE
|
Short-Term Investments
$12.5B
|
CAGR 3-Years
-18%
|
CAGR 5-Years
4%
|
CAGR 10-Years
-4%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Short-Term Investments
$0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Short-Term Investments
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Elite Pharmaceuticals Inc
Glance View
Elite Pharmaceuticals, Inc. engages in the development and manufacture of pharmacological abuse-deterrent opioid products. The company is headquartered in Northvale, New Jersey and currently employs 43 full-time employees. The company went IPO on 2014-02-20. The firm is principally engaged in the development and manufacture of oral, controlled-release products. The firm develops and manufactures generic products, products using controlled-release drug technology, products utilizing abuse deterrent technologies, and it develops and markets (either on its own or by license to other companies) generic controlled-release and abuse deterrent pharmaceutical products. Its segments include Abbreviated New Drug Applications (ANDA) for generic products and New Drug Applications (NDA) for branded products. Elite owns, licenses and contract manufactures products, including Phentermine HCl 37.5mg tablets , Phendimetrazine Tartrate 35mg tablets, Naltrexone HCl 50mg tablets, Isradipine 2.5mg and 5mg capsules, Oxycodone HCl Immediate Release 5mg, 10mg, 15mg, 20mg and 30mg tablets, Trimipramine Maleate Immediate Release 25mg, 50mg and 100mg capsules, among others.
